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Abstract
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on L-tryptophan
produced by fermentation using Escherichia coli KCCM 80152 when used as nutritional additive in feed
and water for drinking for all animal species. The production strain and its recombinant DNA were not
detected in the additive. L-Tryptophan, manufactured by fermentation with E. coli KCCM 80152, does
not give rise to any safety concern with regard to the genetic modification of the production strain.
The use of L-tryptophan produced using E. coli KCCM 80152 in supplementing feed to compensate for
tryptophan deficiency in feedingstuffs is safe for non-ruminant target species. Using unprotected forms
of tryptophan in ruminants can be a risk. The use of L-tryptophan produced by fermentation using
E. coli KCCM 80152 in animal feed presents no concerns to consumers of animal products. Due to the
content of endotoxins, the additive poses a risk for persons handling the additive when exposed by
inhalation. The additive is not considered irritant for skin or eyes and is not considered a skin
sensitiser. The additive under assessment is safe for the environment. The additive under assessment
is regarded as an effective source of the amino acid L-tryptophan for all non-ruminant species. If
L-tryptophan is intended for use in ruminants, it should be protected from ruminal degradation.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from CJ Europe GmbH2 for authorisation of the
product L-Tryptophan, produced using E. coli KCCM80152, when used as a feed additive for all animal
species (category: nutritional additives; functional group: amino acids, their salts and analogues).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). The particulars and documents in
support of the application were considered valid by EFSA as of 21 February 2018.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efficacy of the
product L-Tryptophan produced by fermentation with E. coli KCCM80152, when used as nutritional
additive in feed and water for drinking for all animal species under the proposed conditions of use (see
Section 3.1.4).
1.2. Additional information
L-Tryptophan (minimum content of 98% on dry matter basis) produced by fermentation with six
strains of E. coli (KCCM 11132P, DSM 25084, FERM BP-11200, FERM BP-11354, CGMCC 7.59 or CGMCC
3667) is currently authorised as a nutritional feed additive for use in all animal species.3 The product
under assessment, L-tryptophan produced by E. coli KCCM 80152, has not been previously authorised
as feed additive in the European Union (EU).
L-Tryptophan is authorised for use in food,4 cosmetics5 and as a veterinary medicinal product.6,7
L-Tryptophan is described in the European Pharmacopoeia (2017), monograph 01/2017:1272.
The EFSA Panel on Additives and Products or Substances used in Animal Feed published several
opinions on the safety and efficacy of L-tryptophan produced by different strains of E. coli for all
animal species (EFSA FEEDAP Panel, 2013, 2014a,b, 2015a,b, 2016a,b, 2017a,b, 2019a,b).
The Panel on Dietetic Products, Nutrition and Allergies (NDA) of EFSA issued a scientific opinion on
the substantiation of health claims related to L-tryptophan (EFSA NDA Panel, 2011). The Panel on
Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientific Committee for Food
Safety (VKM) published an opinion on histidine, methionine, S-adenosylmethionine and tryptophan
added to foods and drinks and in food supplements (VKM, 2013) and another on L-tryptophan in food
supplements and energy drinks (VKM, 2016) and concluded that doses ≥ 250 mg/day may represent a
risk of adverse health effects for children, adolescents and adults.
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 CJ Europe GmbH, Ober der Roeth 4, 65824 Schwalbach am Taunus, Germany.
3 Commission implementing regulation (EU) 2017/873 of 22 May 2017 concerning the authorisation of L-tryptophan produced by
Escherichia coli as feed additive for all animal species. OJ L 134, 23.5.2017, p. 14.
4 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009, OJ L 181,
29.6.2013, p. 35.
5 Commission Decision of 9 February 2006 amending Decision 96/335/EC establishing an inventory and a common nomenclature
of ingredients employed in cosmetic products. OJ L 97, 5.4.2006, p. 1–528.
6 Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification
regarding maximum residue limits in foodstuffs of animal origin. OJ L 15, 20.1.2010, p. 1.
7 Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community
procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin,
repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the
Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council. OL L 152, 16.6.2009, p. 11.
L-Tryptophan produced by fermentation using Escherichia coli for all animal species
www.efsa.europa.eu/efsajournal 4 EFSA Journal 2019;17(5):5695
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier8 in support of the authorisation request for the use of L-tryptophan produced by fermentation
using E. coli KCCM 80152 as additive for feed and water for drinking in all animal species.
The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as previous risk assessments by EFSA or other expert bodies, peer-reviewed scientific papers,
other scientific reports and experts’ knowledge, to deliver the present output.
EFSA has verified the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of the L-Tryptophan produced by fermentation with E. coli K12 KCCM
80152 in animal feed. The Executive Summary of the EURL report can be found in Annex A.9
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efficacy of L-tryptophan
produced by fermentation with E. coli KCCM 80152 is in line with the principles laid down in Regulation
(EC) No 429/2008 and the relevant guidance documents: Guidance on nutritional additives (EFSA
FEEDAP Panel, 2012a), Tolerance and efficacy studies in target animals (EFSA FEEDAP Panel, 2011),
Technical Guidance for assessing the safety of feed additives for the environment (EFSA, 2008a),
Guidance for establishing the safety of additives for the consumer (EFSA FEEDAP Panel, 2012b),
Guidance on studies concerning the safety of use of the additive for users/workers (EFSA FEEDAP
Panel, 2012c), Technical Guidance: Microbial studies (EFSA, 2008b), Guidance on microorganisms used
as feed additive or as production organisms (EFSA FEEDAP Panel, 2018).
3. Assessment
L-Tryptophan minimum 98% produced by fermentation using E. coli KCCM 80152 is intended to be
used as a nutritional feed additive under the functional group ‘amino acids, their salts and analogues’
in feed and water for drinking for all animal species.
3.1. Characterisation
3.1.1. Characterisation of the production organism
The susceptibility of the production strain to all antibiotics recommended by EFSA for E. coli in the
2012 guidance (EFSA FEEDAP Panel, 2012d) was assayed by broth microdilution.
3.1.1.1. Information relating to the genetic modification
Characteristics of the recipient or parental microorganism
The recipient strain is E. coli KCCM 11132P, which was derived from E. coli K-12 W3110 by classical
mutagenesis and genetic modification. E. coli KCCM 11132P
This strain has been previously characterised by the FEEDAP Panel in
a previous opinion (EFSA FEEDAP Panel, 2015b), and did not raise safety concerns.
8 FEED dossier reference: FAD-2017-0052.
9 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/jrcsh/files/finrep-fad-2017-0052-tryptophan.pdf
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Characteristics of the donor organism
Description of the genetic modification process
3.1.2. Manufacturing process
The dossier contains information on the production process
16
3.1.3. Characterisation of the additive
L-Tryptophan (International Union of Pure and Applied Chemistry (IUPAC) name: (2S)-2-amino-3-
(1H-indol-3-yl) propanoic acid; synonyms: (S)-a-amino-1-H-indole-3-propanoic acid, L-a-aminoindole-3-
propionic acid, L-a-amino-3-indolepropionic acid, 2-amino-3-indolylpropanoic acid, L-b-3-indolylalanine)
has the Chemical Abstracts Service (CAS) No 73-22-3 and European Inventory of Existing Commercial
Chemical Substances (EINECS) No 200-795-6. The chemical formula is C11H12N2O2, the molecular
weight is 204.23 g/mol. The structural formula is given in Figure 1.
The L-tryptophan content of the product is specified as ≥ 98%, the other components being water
≤ 1%, and crude ash ≤ 1%.18
Figure 1: Structural formula of L-tryptophan
16 Technical dossier/Section II.2.3.1.
18 Technical dossier/Section II.1.3 and Table II.1.3a.
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The analysis of five batches of L-tryptophan showed an average content of tryptophan of 98.8% on
as is basis (range 98.5–99.4%) and moisture was 0.1%.19 On a dry matter basis, the amount of
tryptophan was, on average, 98.9% (range 98.6–99.5%).
The applicant provided additional data on five batches of the additive to determine the amount of
identified matter in the additive.20 On as is basis, the amount of identified material was 99.0%.
Tryptophan was analysed by an unspecified High Performance Liquid Chromatography (HPLC) method.
The specific optical rotation of three batches of the final product was measured by the European
Pharmacopeia method. Analytical values ranged from 30.5° to 31.2°,21 which is within the range
described in the European Pharmacopoeia (30° to 33°) for this amino acid and confirms the identity
of the L-enantiomer.22
3.1.3.1. Impurities
Five batches of the final product were analysed for heavy metals (lead, cadmium and mercury) and
arsenic.23 Lead and arsenic were below the limit of detection (LOD), mercury ranged from below LOD
to 0.023 mg/kg and cadmium from below LOD to 0.21 mg/kg. Copper ranged from 2.1 to 5.4 mg/kg
and zinc ranged from below LOD to 10.4 mg/kg.
Analysis of microbial contamination of the final product (five batches) indicated that Salmonella
spp. (in 25-g samples) was absent whereas total bacterial count, E. coli, yeasts and filamentous fungi
were < 103 CFU/g.24
Mycotoxins were analysed in five batches of the final product.25 Aflatoxins (not specified) ranged
from below LOD to 0.2 lg/kg. Ochratoxin A, zearalenone and deoxinivalenol had concentrations below
LOD (except one batch that had 6 lg ochratoxin A/kg).
Dioxins (polychlorinated dibenzodioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs)) and
dioxin-like polychlorinated biphenyls (PCBs) were analysed in five batches of the final product. Dioxins
(WHO-PCDD/F-TEQ) ranged from 0.16 to 0.33 ng/kg and the sum of dioxins and dioxin like PCBs
(WHO-PCDD/F-PCB-TEQ) ranged from 0.30 to 0.58 ng/kg.26
The endotoxin activity (three batches analysed by European Pharmacopoeia method) ranged from
0.36 to 0.40 IU/mg.27
1,10-Ethylidene-bis-L-tryptophan (EBT) and 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic
acid (MTCA), present in a specific brand of L-tryptophan produced by fermentation, were implicated in
the eosinophilia–myalgia syndrome outbreak that occurred in humans in New Mexico in 1989
(Hertzman et al., 1990). The concentrations of EBT and MTCA were analysed in three batches of the
final product (EurPh method 2.2.29) and were below the LOD in all three batches.28 The maximum
permitted content of EBT (impurity A) and the sum of all other impurities (B-L, including MTCA), in
L-tryptophan, as specified by the European Pharmacopoeia (2010), is 10 mg/kg and 390 mg/kg,
respectively.
Positive controls were included.
19 Technical dossier/Section II/Annex II.1.6. Tryptophan determined by analytical method VDLUFA 4.11.2.
20 Technical dossier/Section II/Annex II.1.4 and supplementary information July 2018/SIN CJ Trp 80152.
21 Technical dossier/Supplementary information December 2018/Annex SIN 1.
22 European Pharmacopoeia monograph 1/2015:1272.
23 Technical dossier/Section II/Annex II.1.6. LOD in mg/kg were 0.01 for mercury, 0.1 for cadmium, 0.2 for zinc and 1 for lead
and arsenic.
24 Technical dossier/Section II/Annex II.1.5.
25 Technical dossier/Section II/Annex II.1.5. LOD (in µg/kg) was 0.1 for aflatoxins, 5 for ochratoxin A, 17 for zearalenone and
134 for deoxynivalenol.
26 Technical dossier/Section II/Annex II.1.6.
27 Technical dossier/Supplementary information July 2018/Annex SIN 01.
28 Technical dossier/Section II/Annexes II.1.8 and Supplementary information July 2018/Annex SIN 02, LOD was 3 mg/kg.
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3.1.3.2. Physical characteristics
The product under assessment is a solid pale brownish odourless powder. Bulk density ranged from
350 to 500 kg/m3.31 Its water solubility is 10.6 g/L at 20°C.32 The hydrogen potential (pH) ranged
from 6.2 to 6.8.33
The particle size distribution (three batches analysed by sieving) showed that the percentages of
particles having a diameter below 88 lm were 73, 75 and 77% (w/w), respectively.34
The dusting potential was analysed (Stauber–Heubach method) in three batches of the product
under assessment. The results ranged from 1.97 to 6.66 g/m3.35
3.1.3.3. Stability and homogeneity
The applicant submitted a study on the shelf-life of the additive and a study on the stability of the
additive in water for drinking performed with the additive under assessment. The rest of the stability
studies (shelf-life at room temperature, stability in premixtures and in feedingstuffs and capacity to
distribute homogeneously in premixtures and in pelleted feed) were performed with L-tryptophan
produced by different E. coli strains (KCCM 80135 or KCCM 11132P) from the same producer (EFSA
FEEDAP Panel, 2015b, 2019c).36 As the production strains share a common lineage (E. coli K12
derivatives), the manufacturing process is the same and the product characteristics are very similar,
the FEEDAP Panel considers that the stability and homogeneity studies performed with L-tryptophan of
the other two production strains are indicative of the stability of the product under assessment. No
information was available on the stability of the additive during feed processing.
The shelf-life of three batches of the additive under assessment was tested at 25  2°C and at
40  2°C when packed in double polyethylene bags for 6 months.37 No losses were observed. No
losses were observed in three batches produced by another strain (KCCM 11132P) stored at 25°C up
to 3 years.
The stability of three batches L-tryptophan produced by another strain (E. coli KCCM 80135) in a
vitamin mineral premixture (containing 4% choline chloride) at a supplementation rate of 0.5% was
tested at 25  2°C for 6 months. The premixture was packed in aluminium vacuum bags. The losses
observed ranged from 0.4 to 2.2% after the 6-month period.38 (VDLUFA method)
The stability of three batches of L-tryptophan produced by another strain (E. coli KCCM 80135) in a
complete feed for chickens for fattening (mash feed based on maize, soybean meal and wheat), at a
supplementation rate of 0.4%, was tested after storage at 25  2°C in aluminium vacuum bags for
3 months. After the 3-month period, the observed losses ranged from 0.5 to 4.6%.39
The capacity of L-tryptophan produced by another strain (E. coli KCCM 80135) to distribute
homogeneously in the premixture described above was studied by analysing 10 subsamples. The
coefficient of variation (CV) was 5.7%.40
The capacity of L-tryptophan produced by another strain (E. coli KCCM 80135) to distribute
homogeneously in a pelleted complete feed for chickens for fattening when supplemented at 0.2%
was studied analysing 10 subsamples. After mixing, the complete feed was preconditioned using water
steam at ≤ 72°C, pelleted at 81°C, dried at 60–65°C and then cooled for 10 min to 23°C. The CV was
2.9%.41 No measurement was performed between mixing and preconditioning (stability during feed
processing).
The stability of the additive under assessment in water for drinking (three batches) was measured
at a concentration of 0.5 g/L when stored at 25 and 40°C for 48 h. Losses were < 1% in both cases.42
31 Technical dossier/Section II/Annex II.3.1.
32 Technical dossier/Section II.1.5.
33 Technical dossier/Section II/Annex II.1.3.
34 Technical dossier/Section II.1.5, table II.1.5a and annex II.1.8.
35 Technical dossier/Supplementary information December 2018/Annex SIN 2.
36 Technical dossier/Supplementary information July 2018/SIN CJ L-trp 80152.
37 Technical dossier/Section II/Annex II.4.2.
38 Technical dossier/Section II/Annex II.4.3.
39 Technical dossier/Section II/Annex II.4.4.
40 Technical dossier/Section II/Annex II.4.7.
41 Technical dossier/Section II/Annex II.4.6.
42 Tehcnical dossier/Section II/Annex II.4.5.
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3.1.3.4. Physico-chemical incompatibilities
No physico-chemical incompatibilities in feed are expected with other additives, medical products or
feed materials.
3.1.4. Conditions of use
It is proposed that L-tryptophan will be used in feeds to achieve an adequate amino acid profile
and to meet the L-tryptophan requirements for all animal species. It can be added directly to
feedingstuffs/complementary feedingstuffs or via premixtures. The additive is also proposed for use in
water for drinking. No inclusion levels have been proposed as the requirements, in quantitative terms,
depend on the species, the physiological state of the animal, the performance level, the environmental
conditions and the amino acid composition of the unsupplemented diet.
3.2. Safety
3.2.1. Safety of the genetic modification
The recipient organism E. coli KCCM 11132P is considered to be safe. The production strain KCCM
80152 contains This trait does not raise safety concern.
The production strain and its recombinant DNA were not detected in the additive. The product
L-tryptophan, manufactured by fermentation with E. coli KCCM 80152, does not give rise to any safety
concern with regard to the genetic modification of the production strain.
3.2.2. Safety for the target species
Tolerance studies are not normally required for highly purified amino acids. Such tolerance studies
with a certain indispensable amino acid will inevitably result in amino acid imbalances, with depression
of feed intake and hence impaired performance and increased nitrogen excretion. This is also the case
for the product under application which contains on average 98.9% L-tryptophan and 1% unidentified
material on a dry matter basis. The endotoxin activity ranged from 0.36 to 0.40 IU/mg. These values
are negligible compared with ca. 1,000 IU/mg commonly found in feedingstuffs (Cort et al., 1990).
Therefore, at the usual conditions of use of the additive in feed, the endotoxins added by the additive
would be insignificant compared to the background in feed.
The L-tryptophan requirements of the target animal species and the safety of the use of this
essential amino acid in non-ruminant and ruminant nutrition were summarised in previous opinions of
the EFSA FEEDAP Panel (2013, 2015a).
Given the high purity of the product, the FEEDAP Panel considers that the use of L-tryptophan
produced with E. coli KCCM 80152 is safe for non-ruminant target species when used to supplement
the diet in appropriate amounts. The FEEDAP Panel reiterates (2015a) that ruminal metabolism of
unprotected L-tryptophan may result in the production of toxic quantities of 3-methylindole (skatole),
which causes pulmonary disease (fog fever; emphysema) in cattle and goats. Consequently, using
unprotected forms of tryptophan in ruminants can be a risk.
The FEEDAP Panel recommended in a previous statement that amino acids, their salts and
analogues should generally not be used in water for drinking because of the risk of imbalances and for
hygiene reasons (EFSA FEEDAP Panel, 2010).
3.2.2.1. Conclusions on safety for the target species
The use of L-tryptophan produced using E. coli KCCM 80152 in supplementing feed to compensate
for tryptophan deficiency in feedingstuffs is safe for non-ruminant target species. Using unprotected
forms of tryptophan in ruminants can be a risk.
The FEEDAP Panel has concerns on the safety of the simultaneous oral administration of
L-tryptophan via water for drinking and feed.
3.2.3. Safety for the consumer
The absorption and metabolic fate of L-tryptophan were described in a previous opinion (EFSA
FEEDAP Panel, 2013).
The amino acid L-tryptophan supplemented to feed will be incorporated into proteins of tissues
and/or products of animal origin and any of their potential excess will be metabolised and excreted.
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Therefore, the composition of tissues and products of animal origin will not be affected by the use of
L-tryptophan in animal nutrition.
The product under assessment is produced by fermentation. Concerns for the consumer would
derive not from the amino acid itself, which will be incorporated into proteins, but from possible
residues from fermentation. Considering that (1) the product originating from E. coli KCCM 80152 is
highly purified (average 98.9% L-tryptophan and 1% unidentified material on a dry matter basis) and
(2) the concentrations of EBT and MTCA are < 3 mg/kg additive, no additional toxicological data are
required.
3.2.3.1. Conclusions on safety for the consumer
The use of L-tryptophan produced by fermentation with E. coli KCCM 80152 in animal nutrition
raises no safety concerns for consumers of animal products.
3.2.4. Safety for the user
The applicant provided an acute inhalation toxicity test, an eye irritation test, a skin irritation test
and a dermal sensitisation test performed with L-tryptophan produced by a different production strain
(E. coli KCCM 11132P or E. coli KCCM 80135).43 As the purity and physical characteristics of the test
item are very similar to the ones of the product under assessment, the production process is the same
and the strains share a common lineage, the FEEDAP Panel considers that the results of the
toxicological studies performed with L-tryptophan originating from those two E. coli strains can be
used to support the safety for the user of L-tryptophan produced with E. coli KCCM 80152.
3.2.4.1. Effects on the respiratory system
The additive contains about 74–77% of particles have a diameter < 88 lm and there is indirect
evidence that the dusting potential is up 6.7 g/m3 (see Section 3.1.3).
In an acute inhalation toxicity study in accordance with the Organisation for Economic Co-operation
and Development (OECD) Guideline 403,44 a group of 10 RccHanTM:WIST strain rats (five males and
five females) were exposed to a concentration of 5.1 mg L-tryptophan (98.5% purity)/l air for 4 h
(nose only exposure system). The signs observed (decreased/increased respiratory rate, hunched
posture, piloerection and wet fur) disappeared on day 4 after exposure. No mortality occurred and no
macroscopic lesions were observed at the necropsy. The 4 h LC50 for acute inhalation toxicity is
considered to be > 5.1 mg/L.
The endotoxin activity in the additive was up to 0.40 IU/mg. The scenario used to estimate the
exposure of persons handling the additive to endotoxins in the dust, based on the EFSA Guidance on
user safety (EFSA FEEDAP Panel, 2012b) is described in the Appendix A. The health-based
recommended threshold for the quantity of inhaled endotoxins per working day is 900 IU, derived
from provisional occupational exposure limits given by the Dutch Expert Committee on Occupational
Safety (DECOS) (Health Council of the Netherlands, 2010) and the UK Health and Safety Executive
(HSE, 2013). Based upon the calculation of the potential endotoxin content in dust, the inhalation
exposure could be up to 1,479 endotoxin IU per working day, indicating thus an inhalation exposure to
endotoxins for persons handling the additive.
3.2.4.2. Effects on skin and eyes
In an in vitro bovine corneal opacity and permeability (BCOP) assay (method B.47 of Commission
Regulation (EC) No 440/2008), 0.75 mL of a concentration of 20% L-tryptophan (w/v, 98.7% purity) in
sodium chloride (0.9% solution) was applied to incubated adult cattle corneas for 4 h.45 Negative
(sodium chloride solution 0.9%) and positive control (imidazole 20% solution in sodium chloride 0.9%)
items were tested concurrently. The two endpoints measured, decreased light transmission through the
cornea (opacity) and increased passage of sodium fluorescein dye through the cornea (permeability)
were combined in an empirically derived formula to obtain an in vitro irritancy score (IVIS). As the IVIS
score for the test item was ≤ 3, no classification is required. The controls performed as expected.
In an in vitro skin irritation study using reconstructed human epidermis model (EPISKINTM) in
accordance with OECD Guideline 439, 10 mg of L-tryptophan (98.7% purity) was applied (triplicate
tissues) topically on the epidermal surface for 15 min, rinsed and followed by a post-exposure
43 Technical dossier/Supplementary information July 2018/SIN CJ L-try 18152/Answer to question 1.
44 Technical dossier/Seciton III/Annex III.3a.
45 Technical dossier/Section III/Annex III.3.3.
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incubation period of 42 h.46 Potential cytotoxicity of the test item was measured by the colorimetric
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay and compared with
negative (10 lL of Dulbecco’s phosphate-buffered saline solution) or positive (10 lL of sodium lauryl
sulphate 5% w/v) controls. The relative mean viability of the test item treated tissues was 110% after
42 h post exposure incubation period. The controls performed as expected. The test item was
considered not irritant for the skin.
In an in vivo skin sensitisation study (local lymph node assay in mouse) in accordance with OECD
Guideline 429, L-tryptophan (98.5% purity) caused no signs of toxicity, visual local skin irritation or
irritation indicated by an ≥ 25% increase in mean ear thickness.47 Consequently, the additive was
classified as non-skin sensitiser.
3.2.4.3. Conclusions on safety for the user
From an acute toxicity inhalation study, there are no indications that the product under assessment
is toxic by inhalation. Nevertheless, the persons handling the additive may be exposed to endotoxins
by inhalation. The additive is not considered irritant for skin or eyes and is not considered a skin
sensitiser.
3.2.5. Safety for the environment
The amino acid L-tryptophan is a physiological and natural component of animals and plants. When
given to animals, it is not excreted as such, but as urea/uric acid, indole-related compounds and
carbon dioxide. The use of the product L-tryptophan in animal nutrition would not lead to any localised
increase in the concentration in the environment. It is concluded that the use of the product under
assessment, produced by E. coli KCCM 80152 as a feed additive does not represent a risk to the
environment.
The production strain E. coli KCCM 80152 and its recombinant DNA were not detected in the final
product. The product does not pose any environmental safety concern associated with the genetic
modification of the production strain.
3.3. Efficacy
Efficacy studies are not required for amino acids naturally occurring in the proteins of plants and
animals. The nutritional role of the amino acid L-tryptophan is well established in the scientific
literature. The additive feed grade L-tryptophan is regarded as an effective source of the amino acid
L-tryptophan.
Overdosing of supplemental L-tryptophan may increase skatole and indole in the hind gut resulting
in boar taint of pork (Zamaratskaia and Squires, 2008).
The efficacy of this essential amino acid in non-ruminant and ruminant nutrition was summarised in
a previous opinion of the EFSA FEEDAP Panel (2014b). The FEEDAP Panel reiterates that, if the
product L-tryptophan is used in ruminants, it should be protected from ruminal degradation.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for specific requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation48 and Good
Manufacturing Practice.
4. Conclusions
The production strain and its recombinant DNA were not detected in the additive. L-Tryptophan,
manufactured by fermentation with E. coli KCCM 80152, does not give rise to any safety concern with
regard to the genetic modification of the production strain.
The use of L-tryptophan produced using E. coli KCCM 80152 in supplementing feed to compensate
for tryptophan deficiency in feedingstuffs is safe for non-ruminant target species. Using unprotected
forms of tryptophan in ruminants can be a risk.
46 Technical dossier/Section III/Annex III.3.4.
47 Technical dossier/Section III/Annex III.3.5.
48 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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The use of L-tryptophan produced by fermentation using E. coli KCCM 80152 in animal feed
presents no concerns to consumers of animal products.
Due to the content of endotoxins, the additive poses a risk for persons handling the additive when
exposed by inhalation. The additive is not considered irritant for skin or eyes and is not considered a
skin sensitiser.
The additive under assessment is safe for the environment.
The additive under assessment is regarded as an effective source of the amino acid L-tryptophan
for all non-ruminant species. If L-tryptophan is intended for use in ruminants, it should be protected
from ruminal degradation.
5. Recommendations
It is recommended that the specification of the additive complies with the European Pharmacopeia
with regard to L-tryptophan impurities.
Chronology
Date Event
29/9/2017 Dossier received by EFSA. Feed grade L-tryptophan produced with Escherichia coli K12 KCCM
80152. Submitted by CJ Europe GmbH
5/10/2017 Reception mandate from the European Commission
21/2/2018 Application validated by EFSA – Start of the scientific assessment
26/4/2018 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientific assessment suspended. Issues: characterisation of the additive,
stability, characterisation of the production strain and of the genetic modification process
21/5/2018 Comments received from Member States
18/5/2018 Reception of the Evaluation report of the European Union Reference Laboratory for Feed Additives
4/7/2018 Reception of supplementary information from the applicant - Scientific assessment re-started
9/10/2018 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientific assessment suspended Issues: Characterisation of the production
strain
18/10/2018 Reception of supplementary information from the applicant – Scientific assessment re-started
30/10/2018 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientific assessment suspended Issues: Characterisation of the additive
6/12/2018 Reception of supplementary information from the applicant - Scientific assessment re-started
14/12/2018 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientific assessment suspended Issues: Characterisation of the additive
6/3/2019 Reception of supplementary information from the applicant – Scientific assessment re-started
3/4/2019 Opinion adopted by the FEEDAP Panel. End of the Scientific assessment
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Appendix A – Safety for the user
The effects of endotoxin inhalation and the exposure limits have been described in a previous
opinion (EFSA FEEDAP Panel, 2015a,b).
Calculation of maximum acceptable levels of exposure from feed additives
The probable exposure time according to EFSA guidance (EFSA FEEDAP Panel, 2012b) for additives
added in premixtures assumes a maximum of 40 periods of exposure per day, each comprising
20 s = 40 9 20 = 800 s/day. With an uncertainty factor of 2, maximum inhalation exposure would
occur for 2 9 800 = 1,600 s = 0.444 h/day. Again, assuming a respiration volume of 1.25 m3/h, the
inhalation volume providing exposure to potentially endotoxin-containing dust would be
0.444 9 1.25 = 0.556 m3/day. This volume should contain no more than 900 IU endotoxin, so the
dust formed from the product should contain no more than 900/0.556 = 1,619 IU/m3.
Calculation of endotoxin content of dust
Two key measurements are required to evaluate the potential respiratory hazard associated with the
endotoxin content of the product (the dusting potential of the product, expressed in g/m3, and the
endotoxin activity of the dust, determined by the Limulus amoebocyte lysate assay (expressed in IU/g)).
If data for the dust are not available, the content of endotoxins of the product can be taken instead. If the
content of endotoxins of the relevant additive is a IU/g and the dusting potential is b g/m3, then the
content of endotoxins of the dust, c IU/m3, is obtained by simple multiplication, a 9 b. This resulting
value is further used for calculation of the potential inhalatory exposure of users to endotoxins from the
additive under assessment (Table A.1) (EFSA FEEDAP Panel, 2012b).
Table A.1: Estimation of user exposure to endotoxins from the additive L-tryptophan produced by
Escherichia coli KCCM 80152, including consideration of using a filter mask FF P2 or FF
P3 as a preventative measure
Calculation identifier Description Amount Source
a Endotoxin content IU/g product 400 Technical dossier
b Dusting potential (g/m3) 6.657 Technical dossier
a 9 b c Endotoxin content in the air (IU/m3) 2,662.8
d No of premixture batches made/working day 40 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
e Time of exposure (s) per production of one
batch
20 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
d 9 e f Total duration of daily exposure/worker (s) 800
g Uncertainty factor 2 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
f 9 g h Refined total duration of daily exposure/worker
(s)
1,600
h/3,600 i Refined total duration of daily exposure (h) 0.44
j Inhaled air (m3) per 8-h working day 10 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
j/8 9 i k Inhaled air during exposure (m3) 0.56
c 9 k l Endotoxin inhaled (IU) during exposure
per 8-h working day
1,479
m Health-based recommended exposure limit of
endotoxin (IU/m3) per 8-h working day
90 Health Council of the
Netherlands, 2010
m 9 j n Health-based recommended exposure
limit of total endotoxin exposure (IU)
per 8-h working day
900
l/10 Endotoxins inhaled (IU) per 8-h working day
reduced by filter mask FF P2 (reduction factor 10)
148
l/20 Endotoxins inhaled (IU) per 8-h working day
reduced by filter mask FF P3 (reduction factor 20)
74
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Annex A – Executive summary of the European Union Reference
Laboratory for Feed Additives on the Methods of Analysis for L-tryptophan
produced by Escherichia coli K12 KCCM 80152
In the current application, authorisation is sought under Article 4(1) for L-tryptophan produced by
Escherichia coli K12 KCCM 80152, under the category/functional group 3(c) ‘nutritional additives’/‘amino
acids, their salts and analogues’, according to Annex I of Regulation (EC) No 1831/2003. Authorisation is
sought for all animal species. L-tryptophan is already authorised as feed additive under Commission
Implementing Regulation (EU) 2017/873. According to the Applicant, the product has a minimum purity
of 98% and it is intended to be mixed either in premixtures or added directly to feedingstuffs or water for
drinking. However, the Applicant did not propose a minimum or maximum L-tryptophan content in
feedingstuffs.
For the quantification of L-tryptophan in the feed additive, premixtures, feedingstuffs and water, the
Applicant submitted a single-laboratory validated analytical method based on High Performance Liquid
Chromatography (HPLC) with photometric detection. However, based on the data provided, the
European Union Reference Laboratory (EURL) cannot recommend this method for official control. The
EURL previously evaluated and recommended (i) the ring-trial validated
EN ISO 13904:2016 method based on HPLC with fluorescence detection (HPLC-FLD) for the
quantification of L-tryptophan in feed additive and premixtures (containing more than 2% of
tryptophan); and (ii) the ring-trial validated Community method based on HPLC-FLD for the
quantification of L-tryptophan in feedingstuffs. Based on the performance characteristics available, the
EURL recommends for official control these two ring-trial validated methods to quantify tryptophan in
the feed additive, premixtures and/or feedingstuffs. In addition, the EURL identified the “L-tryptophan
monograph” of the Food Chemical Codex (FCC) for the identification of the feed additive. Furthermore,
in the frame of the stability studies, the Applicant presented experimental data obtained analysing
tryptophan in water with the VDLUFA official method based on HPLC-FLD dedicated for the
determination of tryptophan in feed. The results presented are considered sufficient to demonstrate
the suitability of the method for the analysis of the amino acid in water. Hence, the EURL recommends
for official control this method to quantify tryptophan in water.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as specified by Article 10 (Commission Regulation (EC) No 378/2005, as last
amended by Regulation (EU) 2015/1761) is not considered necessary.
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